How Paramount Attacked Netflix’s Bid for Warner Bros.

Netflix unveiled an $82.7 billion bid (Project Noble) for Warner Bros. Discovery’s studio and streaming assets on Dec. 5, offering $23.25 cash plus $4.50 in Netflix stock per WBD share and including a $5.8 billion breakup fee, with an expected 12–18 month close. Competing bids from Comcast and Paramount pressed WBD’s board, but Paramount has submitted detailed legal letters arguing that deals with Netflix or Comcast face severe antitrust and regulatory risk — warning a Netflix+HBO Max combination could control roughly 43% of global SVOD subscribers and prompt intense scrutiny over theatrical releases and market-definition arguments. The competing strategies and anticipated regulatory battles create material execution risk for any transaction and are likely to drive volatility in the involved companies’ equity and strategic outcomes for the sector.

Analysis

Market structure: Netflix (NFLX) winning content scale if deal closes but faces concentration risk and a protracted regulatory fight; Warner Bros. Discovery (WBD) shareholders get near-term optionality via $23.25 cash + $4.50 NFLX stock that transfers transactional premium to sellers. Comcast (CMCSA) and Paramount’s bids tighten strategic alternatives and increase political/regulatory salience (Oracle/ORCL ties matter topically), which raises the cost of closing and likely extends timelines to 12–18 months. Cross-asset: expect wider implied vols in NFLX and WBD options, richer credit spreads for WBD/entertainment credits (+50–150bp potential), and downward pressure on theater equities (AMC/CNK) and FX-insensitive flow into U.S. equities and large-cap tech.

Risk assessment: Primary tail risk is regulatory blockade (DOJ/FTC/EC) — assign a 30–55% probability of substantial remedies or divestitures given cited 43% SVOD share figure; second-order risks include talent/production flight and theatrical distribution shrinkage. Time horizons: immediate (days) = volatility spikes and information arbitrage; short-term (30–90 days) = HSR/filings and lobbying; long-term (12–24 months) = integration/talent contracts and content cadence. Hidden dependencies: behavioral remedies (theatrical windows, non-exclusivity) may be accepted, preserving partial value but reducing synergies.

Trade implications: Merger-arb WBD if spread offers >6% annualized (12–18 month close) with a tactical hedge short NFLX equal to the $4.50 stock exposure per WBD share using short-dated calls to cap upside. Buy 9–15 month NFLX downside protection (1–2% portfolio in 12m puts 20% OTM or put spreads) to monetize elevated regulatory risk; consider short small positions (0.5–1%) in theater names AMC/CNK for 6–12 months. Reduce outright long exposure to CMCSA by 1–2% unless their alternative path (spin/divest) becomes clearer.

Contrarian angles: Consensus overstresses total-block risk and underweights a negotiated outcome with remedies; historical parallel: AT&T/TimeWarner faced heavy scrutiny but closed after behavioral/legal negotiation — implies a nontrivial chance (20–40%) deal survives with concessions. Mispricing opportunity: if WBD spread implies <6% annualized, the market is overpricing regulatory closure; conversely, if NFLX IV spikes >40% for >30 days, sell premium via calendar/verticals. Unintended consequence: a blocked deal could lift Paramount/other bidders temporarily but leave WBD operationally weakened; position sizing must account for a binary 30–50% downside in worst-case block scenario.

Key Decisions for Investors

• Establish a merger-arb long position in WBD sized at 2–3% of portfolio if the current spread implies >=6% annualized return assuming a 12–18 month close; hedge the $4.50 per-share NFLX equity component by shorting NFLX calls or delta-equivalent stock short equal to $4.50/WBD-share price exposure.
• Allocate 1–2% of portfolio to NFLX downside protection: buy 12-month puts ~20% OTM or structured put spreads to limit cost; if NFLX implied vol >40% persistently, sell calendar spreads (long-dated long, short near-dated) to monetize premium.
• Take a small tactical short (0.5–1% portfolio) in theater exhibitors AMC and CNK for 6–12 months anticipating content diversion to streaming; size to limit gamma risk and exit on any confirmed long-term theatrical commitments from acquirer within 90 days.
• Trim CMCSA exposure by 1–2% unless Comcast clarifies a non-stock-heavy structure within 30 days; re-allocate trimmed capital to ORCL/lobbying alpha plays (0.5–1%) if evidence of political/regulatory facilitation from Ellison emerges.
• Only enter or increase WBD merger-arb if regulatory milestones are favorable: HSR filing within 30 days without early DOJ/FTC opposition and no immediate EC reference within 60–90 days; if either trigger occurs, widen hedges and reduce position size by 50%.